Brief: Veracyte Q3 Revenue USD 131.9 Million Vs. IBES Estimate USD 124.6 Million
04/11/2025 21:05
Nov 04 (Reuters) - Veracyte Q3 net income USD 19.1 million. Q3 gross margin 69% Q3 adjusted operating expenses USD 58.6 million outlook FY revenue USD 506-510 million
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina